Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Saddle pulmonary embolism in a pediatric patient with nephrotic syndrome and recent COVID-19 pneumonia: A case report

Thomas Cristoforo, DOa, Genevieve McKinley, MDa,⁎, Patricia Ambrosio, DOb

a Pediatric Emergency Medicine Fellow, Arnold Palmer Hospital, Orlando, FL, United States of America
b Pediatric Emergency Medicine Attending, Arnold Palmer Hospital, Orlando, FL, United States of America

Abstract

Article history:
Received 23 March 2021
Accepted 7 April 2021

The pediatric population accounts for a small portion of those with severe disease related to COVID-19. There are few published reports of hypercoagulable states in children with COVID-19. We describe an 11-year-old male with nephrotic syndrome who required inpatient treatment for COVID-19 pneumonia eight weeks prior. He returned to the emergency department with vomiting, tachypnea and was found to have a pulmonary embolism. In this case report, we discuss the risk factors for, presentation and evaluation of hypercoagulable state and its relation to COVID-19 in a pediatric patient.

© 2021 Published by Elsevier Inc.

1. Background

In 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread globally from Wuhan, China and resulted in an acute respiratory illness pandemic. This virus was renamed COVID-19 by The World Health Organization (WHO). The clinical course of COVID-19 is often accompanied by a hyperinflammatory response and systemic coagulation derangement [1], with elevated inflammatory markers including a markedly elevated D-dimer level [2].

Pulmonary embolism (PE) is rare in children, with a reported incidence of 8.6–57 in 100,000 in hospitalized children and 0.14–0.9 in 100,000 when studying the general population of non-hospitalized children [4]. Patients with a severe presentation of COVID-19 infection, in addition to those with COVID-19 and underlying risk factors for thromboembolism, may benefit from prophylactic anticoagulation. We aim to discuss the risk factors, presentation and evaluation of pulmonary embolism and to support the importance for pharmacologic prophylaxis.

2. Case

An 11-year-old male with obesity, recently diagnosed nephrotic syndrome (four months prior) and COVID-19 pneumonia (eight weeks prior) presented to the pediatric emergency department with a chief complaint of non-bloody, non-bilious vomiting for the past three days. Associated symptoms were shortness of breath, fatigue, weight gain, lower extremity swelling, and pain in the right buttocks. His only active home medication was prednisone 40 mg every other day.

Vital signs on arrival were notable for tachycardia to 173 beats per minute and tachypnea to 48 breaths per minute, blood pressure 100/50, oxygen saturation 95–96% on room air, although would decrease to 91–92% intermittently. His body mass index was 39. Physical exam was significant for ill appearance, tachycardia, tachypnea, and poor distal perfusion with cool extremities, but no adventitious heart or lung sounds, and palpable central and peripheral pulses.

Chest and abdominal X-rays were unremarkable. POCUS revealed no ascites, no pleural effusion and no pericardial effusion. Laboratory evaluation revealed leukocytosis of 17,900/ul, hemoglobin of 16.8 g/dL, mild thrombocytopenia of 155,000/ul, hypoalbuminemia of 1.6 g/dL and proteinuria of 3+ protein with a urine protein-to-creatinine ratio of 3.7, consistent with his nephrotic syndrome. Electrocardiogram (ECG) was indicative of right heart strain. (Fig. 1) D-dimer was markedly elevated at 74,443 ng/ml. CT-angiography of his chest was obtained and revealed a saddle pulmonary embolism extending into the segmental and subsegmental branches bilaterally with evidence of right heart strain. (Fig. 2) The patient was treated with heparin and tissue plasminogen activator (tPA). He was admitted to the Pediatric Intensive Care Unit where he was also treated with systemic glucocorticoids, antithrombin III infusions, and enalapril for hypertension and to decrease protein wasting. He was successfully transitioned to warfarin and discharged home on day 21.

3. Discussion

Evidence suggests coagulation function is significantly deranged during COVID-19 infection and may predispose patients to arterial and venous thrombotic complications due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis [3].
Nephrotic syndrome is one of the most common pediatric kidney diseases, with an incidence of 2–7 per 100,000 [4]. Venous thromboembolism (VTE) occurs in roughly 3% of children with nephrotic syndrome, though incidence approaches 25% in high-risk groups [4].

Nephrotic syndrome produces a hypercoagulable state due to thrombocytosis, and hemostatic abnormalities, including decreased levels of antithrombin III, free protein S, and plasminogen secondary to urinary losses. In addition, our patient was at increased risk for thromboembolic events due to obesity, second-hand smoke exposure, prolonged immobilization due to virtual school, and multiple recent hospital admissions.

Currently, there are no standardized recommendations for pharmacologic prophylaxis of VTE for pediatric patients diagnosed with COVID-19. A handful of children’s hospitals across the United States have implemented algorithms for anticoagulation in COVID-19 patients. Recommendations for initiation of pharmacologic prophylactic anticoagulation include patients with COVID-19 plus risk factors for severe disease, such as patients admitted to the ICU or those with Multisystem Inflammatory Syndrome in Children (MIS-C), d-dimer over two times the upper limit of normal or those with significant elevation of markers of inflammation (CRP, ESR, or fibrinogen), or additional VTE risk factors in personal or family medical history, medications or immobility.

4. Conclusion

This case highlights the risk of subsequent thrombotic complications in pediatric patients following COVID-19 infection and supports the need for standardized guidelines for pharmacologic prophylaxis for VTE in patients with COVID-19 and risk factors for thromboembolism. Pulmonary embolism is a rare yet potentially fatal finding in the pediatric population. Due to its rarity, it is crucial to raise awareness about its increased risk in combination with COVID-19 to avoid potential misdiagnoses on initial presentation [5].

Declaration of Competing Interest

None.

References

[1] Rotzinger DC, Beigelman-Aubry C, von Garnier C, Qanadli SD. Pulmonary embolism in patients with COVID-19: time to change the paradigm of computed tomography. Thromb Res. 2020;190:58–9. https://doi.org/10.1016/j.thromres.2020.04.011 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151364/.
[2] Price LC, McCabe C, Garland B, Wort SJ. Thrombosis and COVID-19 pneumonia: the clot thickens! Eur Respir J. 2020;56(1):2001608 Published 2020 Jul 30.
[3] Di Tano G, Moschini L, Loffi M, Galeazzi G, Testa S, Danzi GB. Late pulmonary embolism after COVID-19 pneumonia despite adequate rivaroxaban treatment. EJCRIM. 2020;7. https://doi.org/10.12890/2020_001790 https://www.ejcrim.com/index.php/EJCRIM/article/view/1790.
[4] Agha BS, Sturm JJ, Simon HK, Hirsh DA. Pulmonary embolism in the pediatric emergency department. Pediatrics. 2013 Oct;132(4):663–7. https://doi.org/10.1542/peds.2013-0126 Epub 2013 Sep 2. PMID: 23999960 https://pediatrics.aappublications.org/content/132/4/663.short.
[5] Porfidia A, Valeriani E, Pola R, Porreca E, Rutjes AWS, Di Nisio M. Venous thromboembolism in patients with COVID-19: systematic review and meta-analysis. Thromb Res. 2020;196:67–74. https://doi.org/10.1016/j.thromres.2020.08.020 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7420982/.